OREXIGEN THERAPEUTICS INC's ticker is and the CUSIP is 686164AB0. A total of 3 filers reported holding OREXIGEN THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $3,550,000 | -25.6% | 10,000,000 | 0.0% | 0.43% | -29.4% |
| Q3 2017 | $4,769,000 | -5.1% | 10,000,000 | 0.0% | 0.61% | -22.3% |
| Q2 2017 | $5,025,000 | -8.2% | 10,000,000 | 0.0% | 0.78% | -16.2% |
| Q1 2017 | $5,475,000 | +82.5% | 10,000,000 | 0.0% | 0.93% | +54.4% |
| Q4 2016 | $3,000,000 | +13.2% | 10,000,000 | 0.0% | 0.60% | +20.8% |
| Q3 2016 | $2,650,000 | – | 10,000,000 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Telemetry Investments, L.L.C. | 9,826,000 | $2,358,000 | 1.48% |
| SILVERBACK ASSET MANAGEMENT LLC | 12,000,000 | $3,300,000 | 1.00% |
| BVF INC/IL | 10,000,000 | $2,650,000 | 0.50% |
| Partner Investment Management, L.P. | 403,000 | $111,000 | 0.16% |
| PFM Health Sciences, LP | 16,072,000 | $4,446,000 | 0.13% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 21,414,000 | $5,934,000,000 | 0.09% |
| Verition Fund Management LLC | 2,066,000 | $547,000 | 0.06% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 10,653,000 | $2,943,000 | 0.05% |
| WOLVERINE ASSET MANAGEMENT LLC | 6,000,000 | $1,623,000 | 0.02% |
| Orbimed Advisors | 5,210,000 | $1,441,000 | 0.02% |